Wednesday, June 10, 2026

pharma Β· Metastatic Melanoma Β· Unresectable Melanoma Β· IOVA

Iovance Biotherapeutics

Iovance Biotherapeutics clinical programs β€” 21 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

825 Industrial Rd, Suite 400, San Carlos, California 94070, US HQ
2007 Founded
916 Employees
Public company Type
IOVA Β· NYSE Ticker
Company details
Status
Public
HQ
825 Industrial Rd, Suite 400, San Carlos, California 94070, US
Founded
2007
Employees
916
Programs
36
Drugs
26
Patents
94
Intelligence Β· Clinical Programs

Iovance Biotherapeutics projects

21 ClinicalTrials.gov programs sponsored by Iovance Biotherapeutics.

Iovance Biotherapeutics has 21 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. Aldesleukin

    Iovance Biotherapeutics B.V.

    Bone Sarcoma

    phase 2 mab active

    1 trial
  2. Autologous Tumor Infiltrating Lymphocytes MDA-TIL

    Iovance Biotherapeutics B.V.

    Malignant Solid Neoplasm

    phase 2 mab terminated

    1 trial
  3. C-145-04

    Iovance Biotherapeutics B.V.

    Recurrent, metastatic, or persistent Cervical Carcinoma

    phase 2 small molecule active

    1 trial
  4. Cyclophosphamide

    Iovance Biotherapeutics B.V.

    Clinical Stage IV Cutaneous Melanoma AJCC v8

    phase 2 small molecule completed

    1 trial
  5. Cyclophosphamide

    Iovance Biotherapeutics B.V.

    Metastatic Bladder Urothelial Carcinoma

    phase 2 small molecule terminated

    1 trial
  6. E7 TCR-T cells

    Iovance Biotherapeutics B.V.

    Cervical Cancer

    phase 2 mab active

    1 trial
  7. E7 TCR-T cells

    Iovance Biotherapeutics B.V.

    HPV-Associated Cervical Carcinoma

    phase 2 mab active

    1 trial
  8. IOV-3001

    Iovance Biotherapeutics B.V.

    Unresectable Melanoma

    phase 2 mab active

    1 trial
  9. IOV-4001

    Iovance Biotherapeutics B.V.

    Unresectable Melanoma

    phase 2 mab active

    1 trial
  10. IOV-COM-202

    Iovance Biotherapeutics B.V.

    Neoplasm

    phase 2 small molecule active

    1 trial
  11. IOV-LUN-202

    Iovance Biotherapeutics B.V.

    Metastatic Non-Small-Cell Lung Cancer

    phase 2 small molecule active

    1 trial
  12. IOV-MEL-202

    Iovance Biotherapeutics B.V.

    Previously treated advanced melanoma

    phase 2 small molecule active

    1 trial
  13. LN-145

    Iovance Biotherapeutics B.V.

    Cervical Carcinoma

    phase 2 mab terminated

    1 trial
  14. LN-145

    Iovance Biotherapeutics B.V.

    Cutaneous Squamous Cell Carcinoma

    phase 2 mab active

    1 trial
  15. LN-145

    Iovance Biotherapeutics B.V.

    Metastatic Non Small Cell Lung Cancer

    phase 2 mab active

    1 trial
  16. LN-145

    Iovance Biotherapeutics B.V.

    Non Small Cell Lung Cancer

    phase 2 mab terminated

    1 trial
  17. LN-145

    Iovance Biotherapeutics B.V.

    Squamous Cell Carcinoma of the Head and Neck

    phase 2 mab completed

    1 trial
  18. Lifileucel

    Iovance Biotherapeutics B.V.

    Metastatic Melanoma

    phase 2 mab completed

    2 trials
  19. Lifileucel

    Iovance Biotherapeutics B.V.

    Melanoma (Skin Cancer)

    phase 2 mab active

    1 trial
  20. Lifileucel

    Iovance Biotherapeutics B.V.

    Endometrial Cancer

    phase 2 mab active

    1 trial
  21. Tumor infiltrating lymphocytes (TIL) LN-145

    Iovance Biotherapeutics B.V.

    Metastatic Triple Negative Breast Cancer

    phase 2 small molecule completed

    1 trial

Frequently asked questions

How many clinical projects does Iovance Biotherapeutics have?

21 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.